PATENT CLAIM ANALYSIS

Application Number: 16049390
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "464000"]

Abstract:
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Claim (Index 4):
The dosage form according to  claim 1 , wherein the mean blood plasma concentration of oxymorphone 12 hours after administration is between about 36.8% and 95.8% that of the highest mean blood plasma concentration of oxymorphone.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.18919
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11427438', '10190192', '11680432', '12716973', '14336753']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.797757308849306
- 35 USC 102 Novelty (BERT): 0.583398728321879
- Combined Prediction Score: 0.7763214507965632
- Mean Citation Score: 463.99081000000007
- Max Citation Score: 525.475
- Similarity Product: 384.1035924106836

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test